Chemoprevention of hepatocellular carcinoma by acyclic retinoid

Frontiers in Bioscience

Volumn 16, Issue 2, 2011, Pages 759-769

  Shimizu, Masahito ^a   Sakai, Hiroyasu ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoprevention; HCC; Phosphorylated RXR alpha; Retinoid; Review

Indexed keywords

3,7,11,15-TETRAMETHYL-2,4,6,10,14-HEXADECAPENTAENOIC ACID; DRUG DERIVATIVE; PERETINOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR;

CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; LIVER TUMOR; PHYSIOLOGY; REVIEW;

CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; CLONAL DELETION; HUMANS; LIVER NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRETINOIN;

EID: 79955037674     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3718     Document Type: Article

References (62)

1. El-Serag, H. B.; Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576 (2007) (Pubitemid 46890874)
2. Parikh, S.; Hyman, D. Hepatocellular cancer: a guide for the internist. Am J Med 120:194-202 (2007) (Pubitemid 46341174)
3. Ince, N.: Wands, J. R. The increasing incidence of hepatocellular carcinoma. N Engl J Med 340:798-799 (1999) (Pubitemid 29114300)
4. Kumada, T.: Nakano, S.: Takeda, I.: Sugiyama, K.: Osada, T.: Kiriyama, S.: Sone, Y.: Toyoda, H.: Shimada, S.: Takahashi, M.: Sassa, T. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25:87-92 (1997) (Pubitemid 27014990)
5. Koda, M.: Murawaki, Y.: Mitsuda, A.: Ohyama, K.: Horie, Y.: Suou, T.: Kawasaki, H.: Ikawa, S. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 88:529-537 (2000) (Pubitemid 30056925)
6. Shimizu, M.: Takai, K.: Moriwaki, H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 100:369-374 (2009)
7. Moriwaki, H.: Shimizu, M.: Okuno, M.: Nishiwaki-Matsushima, R. Chemoprevention of liver carcinogenesis with retinoids: Basic and clinical aspects. Hepatol Res 37 Suppl 2:S299-302 (2007)
8. Okuno, M.: Kojima, S.: Akita, K.: Matsushima-Nishiwaki, R.: Adachi, S.: Sano, T.: Takano, Y.: Takai, K.: Obora, A.: Yasuda, I.: Shiratori, Y.: Okano, Y.: Shimada, J.: Suzuki, Y.: Muto, Y.: Moriwaki, H. Retinoids in liver fibrosis and cancer. Front Biosci 7:d204-218 (2002)
9. Matsushima-Nishiwaki, R.: Okuno, M.: Adachi, S.: Sano, T.: Akita, K.: Moriwaki, H.: Friedman, S. L.: Kojima, S. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 61:7675-7682 (2001) (Pubitemid 32995065)
10. Sporn, M. B.: Newton, D. L. Chemoprevention of cancer with retinoids. Fed Proc 38:2528-2534 (1979) (Pubitemid 10249287)
11. Matsushima-Nishiwaki, R.: Okuno, M.: Takano, Y.: Kojima, S.: Friedman, S. L.: Moriwaki, H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24:1353-1359 (2003) (Pubitemid 37038825)
12. Kanamori, T.: Shimizu, M.: Okuno, M.: Matsushima-Nishiwaki, R.: Tsurumi, H.: Kojima, S.: Moriwaki, H. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci 98:431-437 (2007) (Pubitemid 46195617)
13. Tatebe, H.: Shimizu, M.: Shirakami, Y.: Sakai, K.: Yasuda, Y.: Tsurumi, H.: Moriwaki, H. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 285:210-217 (2009)
14. Muto, Y.: Moriwaki, H.: Ninomiya, M.: Adachi, S.: Saito, A.: Takasaki, K. T.: Tanaka, T.: Tsurumi, K.: Okuno, M.: Tomita, E.: Nakamura, T.: Kojima, T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334:1561-1567 (1996) (Pubitemid 26177483)
15. Muto, Y.: Moriwaki, H.: Saito, A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340:1046-1047 (1999) (Pubitemid 29157643)
16. Takai, K.: Okuno, M.: Yasuda, I.: Matsushima-Nishiwaki, R.: Uematsu, T.: Tsurumi, H.: Shiratori, Y.: Muto, Y.: Moriwaki, H. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 48:39-45 (2005) (Pubitemid 40529209)
17. Okita, K.: Matsui, O.: Kumada, H.: Tanaka, K.: Kaneko, S.: Moriwaki, H.: Izumi, N.: Okusaka, T.: Ohashi, Y.: Makuuchi, M. Effect of peretinoin on recurrence ofhepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. Peretinoin Study Group. J Clin Oncol 28 Suppl 7s:4024 (2010)
18. Germain, P.: Chambon, P.: Eichele, G.: Evans, R. M.: Lazar, M. A.: Leid, M.: De Lera, A. R.: Lotan, R.: Mangelsdorf, D. J.: Gronemeyer, H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 58:712-725 (2006) (Pubitemid 44833741)
19. Germain, P.: Chambon, P.: Eichele, G.: Evans, R. M.: Lazar, M. A.: Leid, M.: De Lera, A. R.: Lotan, R.: Mangelsdorf, D. J.: Gronemeyer, H. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 58:760-772 (2006) (Pubitemid 44833744)
20. Michalik, L.: Auwerx, J.: Berger, J. P.: Chatterjee, V. K.: Glass, C. K.: Gonzalez, F. J.: Grimaldi, P. A.: Kadowaki, T.: Lazar, M. A.: O'Rahilly, S.: Palmer, C. N.: Plutzky, J.: Reddy, J. K.: Spiegelman, B. M.: Staels, B.: Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58:726-741 (2006) (Pubitemid 44833742)
21. Altucci, L.: Gronemeyer, H. The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193 (2001) (Pubitemid 33741893)
22. Altucci, L.: Leibowitz, M. D.: Ogilvie, K. M.: De Lera, A. R.: Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6:793-810 (2007) (Pubitemid 47504871)
23. de The, H.: Marchio, A.: Tiollais, P.: Dejean, A. A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature 330:667-670 (1987) (Pubitemid 18005585)
24. Sever, C. E.: Locker, J. Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol Carcinog 4:138-144 (1991)
25. Ando, N.: Shimizu, M.: Okuno, M.: Matsushima-Nishiwaki, R.: Tsurumi, H.: Tanaka, T.: Moriwaki, H. Expression of retinoid X receptor alpha is decreased in 3′-methyl-4-dimethylaminoazobenzene-induced hepatocellular carcinoma in rats. Oncol Rep 18:879-884 (2007)
26. Alvarez, S.: Germain, P.: Alvarez, R.: Rodriguez-Barrios, F.: Gronemeyer, H.: de Lera, A. R. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. Int J Biochem Cell Biol 39:1406-1415 (2007) (Pubitemid 47031031)
27. Matsushima-Nishiwaki, R.: Shidoji, Y.: Nishiwaki, S.: Yamada, T.: Moriwaki, H.: Muto, Y. Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol Cell Endocrinol 121:179-190 (1996) (Pubitemid 26394727)
28. Adachi, S.: Okuno, M.: Matsushima-Nishiwaki, R.: Takano, Y.: Kojima, S.: Friedman, S. L.: Moriwaki, H.: Okano, Y. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 35:332-340 (2002) (Pubitemid 34106372)
29. Yoshimura, K.: Muto, Y.: Shimizu, M.: Matsushima-Nishiwaki, R.: Okuno, M.: Takano, Y.: Tsurumi, H.: Kojima, S.: Okano, Y.: Moriwaki, H. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci 98:1868-1874 (2007) (Pubitemid 350002191)
30. Lee, H. Y.: Suh, Y. A.: Robinson, M. J.: Clifford, J. L.: Hong, W. K.: Woodgett, J. R.: Cobb, M. H.: Mangelsdorf, D. J.: Kurie, J. M. Stress pathway activation induces phosphorylation of retinoid X receptor. J Biol Chem 275:32193-32199 (2000)
31. Solomon, C.: White, J. H.: Kremer, R. Mitogenactivated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J Clin Invest 103:1729-1735 (1999) (Pubitemid 29534367)
32. Macoritto, M.: Nguyen-Yamamoto, L.: Huang, D. C.: Samuel, S.: Yang, X. F.: Wang, T. T.: White, J. H.: Kremer, R. Phosphorylation of the human retinoid X receptor alpha at serine 260 impairs coactivator(s) recruitment and induces hormone resistance to multiple ligands. J Biol Chem 283:4943-4956 (2008)
33. Yamazaki, K.: Shimizu, M.: Okuno, M.: Matsushima-Nishiwaki, R.: Kanemura, N.: Araki, H.: Tsurumi, H.: Kojima, S.: Weinstein, I. B.: Moriwaki, H. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56:1557-1563 (2007) (Pubitemid 350033194)
34. Kanemura, N.: Tsurumi, H.: Okuno, M.: Matsushima-Nishiwaki, R.: Shimizu, M.: Moriwaki, H. Retinoid X receptor alpha is highly phosphorylated in retinoic acidresistant HL-60R cells and the combination of 9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leuk Res 32:884-892 (2008)
35. Lattuada, D.: Vigano, P.: Mangioni, S.: Sassone, J.: Di Francesco, S.: Vignali, M.: Di Blasio, A. M. Accumulation of retinoid X receptor-alpha in uterine leiomyomas is associated with a delayed ligand-dependent proteasomemediated degradation and an alteration of its transcriptional activity. Mol Endocrinol 21:602-612 (2007)
36. Yamada, Y.: Shidoji, Y.: Fukutomi, Y.: Ishikawa, T.: Kaneko, T.: Nakagama, H.: Imawari, M.: Moriwaki, H.: Muto, Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 10:151-158 (1994) (Pubitemid 24257510)
37. Araki, H.: Shidoji, Y.: Yamada, Y.: Moriwaki, H.: Muto, Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun 209:66-72 (1995)
38. Muto, Y.: Moriwaki, H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 73:1389-1393 (1984) (Pubitemid 15243582)
39. Fukutomi, Y.: Omori, M.: Muto, Y.: Ninomiya, M.: Okuno, M.: Moriwaki, H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn J Cancer Res 81:1281-1285 (1990)
40. Nakamura, N.: Shidoji, Y.: Yamada, Y.: Hatakeyama, H.: Moriwaki, H.: Muto, Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 207:382-388 (1995)
41. Nakamura, N.: Shidoji, Y.: Moriwaki, H.: Muto, Y. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha. Biochem Biophys Res Commun 219:100-104 (1996) (Pubitemid 26071610)
42. Yasuda, I.: Shiratori, Y.: Adachi, S.: Obora, A.: Takemura, M.: Okuno, M.: Shidoji, Y.: Seishima, M.: Muto, Y.: Moriwaki, H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 36:660-671 (2002) (Pubitemid 34499404)
43. Shimizu, M.: Suzui, M.: Deguchi, A.: Lim, J. T.: Xiao, D.: Hayes, J. H.: Papadopoulos, K. P.: Weinstein, I. B. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. Clin Cancer Res 10:6710-6721 (2004) (Pubitemid 39346569)
44. Suzui, M.: Shimizu, M.: Masuda, M.: Lim, J. T.: Yoshimi, N.: Weinstein, I. B. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther 3:309-316 (2004) (Pubitemid 39193706)
45. Suzui, M.: Masuda, M.: Lim, J. T.: Albanese, C.: Pestell, R. G.: Weinstein, I. B. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 62:3997-4006 (2002) (Pubitemid 34791066)
46. Shimizu, M.: Suzui, M.: Deguchi, A.: Lim, J. T.: Weinstein, I. B. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res 10:1130-1140 (2004) (Pubitemid 38198915)
47. Kagawa, M.: Sano, T.: Ishibashi, N.: Hashimoto, M.: Okuno, M.: Moriwaki, K.: Suzuki, R.: Kohno, H.: Tanaka, T. An acyclic retinoid, NIK-333, inhibits Ndiethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis 25:979-985 (2004) (Pubitemid 38898636)
48. Sano, T.: Kagawa, M.: Okuno, M.: Ishibashi, N.: Hashimoto, M.: Yamamoto, M.: Suzuki, R.: Kohno, H.: Matsushima-Nishiwaki, R.: Takano, Y.: Tsurumi, H.: Kojima, S.: Friedman, S. L.: Moriwaki, H.: Tanaka, T. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGFalpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer 51:197-206 (2005) (Pubitemid 40734720)
49. Shao, R. X.: Otsuka, M.: Kato, N.: Taniguchi, H.: Hoshida, Y.: Moriyama, M.: Kawabe, T.: Omata, M. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 128:86-95 (2005) (Pubitemid 40039961)
50. Komi, Y.: Sogabe, Y.: Ishibashi, N.: Sato, Y.: Moriwaki, H.: Shimokado, K.: Kojima, S. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab Invest 90:52-60 (2010)
51. Slaughter, D. P.: Southwick, H. W.: Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963-968 (1953)
52. Moriwaki, H.: Yasuda, I.: Shiratori, Y.: Uematsu, T.: Okuno, M.: Muto, Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 3:727-731 (1997) (Pubitemid 27244339)
53. Obora, A.: Shiratori, Y.: Okuno, M.: Adachi, S.: Takano, Y.: Matsushima-Nishiwaki, R.: Yasuda, I.: Yamada, Y.: Akita, K.: Sano, T.: Shimada, J.: Kojima, S.: Okano, Y.: Friedman, S. L.: Moriwaki, H. Synergistic induction of apoptosis by acyclic retinoid and interferonbeta in human hepatocellular carcinoma cells. Hepatology 36:1115-1124 (2002) (Pubitemid 35253427)
54. Habu, D.: Shiomi, S.: Tamori, A.: Takeda, T.: Tanaka, T.: Kubo, S.: Nishiguchi, S. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292:358-361 (2004) (Pubitemid 38944260)
55. Mizuta, T.: Ozaki, I.: Eguchi, Y.: Yasutake, T.: Kawazoe, S.: Fujimoto, K.: Yamamoto, K. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106:867-872 (2006) (Pubitemid 43238454)
56. Ikeda, K.: Arase, Y.: Saitoh, S.: Kobayashi, M.: Suzuki, Y.: Suzuki, F.: Tsubota, A.: Chayama, K.: Murashima, N.: Kumada, H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232 (2000) (Pubitemid 30614654)
57. Kubo, S.: Nishiguchi, S.: Hirohashi, K.: Tanaka, H.: Shuto, T.: Yamazaki, O.: Shiomi, S.: Tamori, A.: Oka, H.: Igawa, S.: Kuroki, T.: Kinoshita, H. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963-967 (2001) (Pubitemid 32466235)
58. Tatebe, H.: Shimizu, M.: Shirakami, Y.: Tsurumi, H.: Moriwaki, H. Synergistic growth inhibition by 9-cisretinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res 14:2806-2812 (2008)
59. Shimizu, M.: Moriwaki, H. Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment. PPAR Res 2008:181047 (2008)
60. Suzui, M.: Sunagawa, N.: Chiba, I.: Moriwaki, H.: Yoshimi, N. Acyclic retinoid, a novel synthetic retinoid, induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle-and differentiation-related molecules in human colon carcinoma cells. Int J Oncol 28:1193-1199 (2006)
61. Sakabe, T.: Tsuchiya, H.: Endo, M.: Tomita, A.: Ishii, K.: Gonda, K.: Murai, R.: Takubo, K.: Hoshikawa, Y.: Kurimasa, A.: Ishibashi, N.: Yanagida, S.: Shiota, G. An antioxidant effect by acyclic retinoid suppresses liver tumor in mice. Biochem Pharmacol 73:1405-1411 (2007) (Pubitemid 46463951)
62. Nakagawa, T.: Shimizu, M.: Shirakami, Y.: Tatebe, H.: Yasuda, I.: Tsurumi, H.: Moriwaki, H. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett 273:250-256 (2009)